Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function

Next Previous
X
Search
Trial Profile

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solriamfetol (Primary)
  • Indications Hypersomnia
  • Focus Therapeutic Use
  • Acronyms SHARP
  • Sponsors Axsome Therapeutics; Jazz Pharmaceuticals Inc

    • Most Recent Events

    • 29 May 2024 According to an Axsome Therapeutics media release, data from the study will be presented at at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), being held June 1-5, 2024, in Houston, Texas.
    • 18 Apr 2024 Results assessing whether solriamfetol, a dopamine-norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adults with obstructive sleep apnea presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 07 Dec 2023 According to an Axsome Therapeutics media release, Dr. Bogan will provide an overview of this study at the virtual investor event and conference call.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top